Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) CEO Chad Robins sold 37,263 shares of the company’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $15.19, for a total transaction of $566,024.97. Following the completion of the sale, the chief executive officer directly owned 2,180,518 shares […]

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 30,941 shares of the firm’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $14.83, for a total transaction of $458,855.03. Following the completion of the sale, the chief operating officer owned 434,188 shares of […]

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) CEO Chad Robins sold 83,332 shares of the company’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $14.41, for a total transaction of $1,200,814.12. Following the completion of the transaction, the chief executive officer owned 2,217,781 shares of […]

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) traded down 5.2% during trading on Monday . The stock traded as low as $14.15 and last traded at $14.0360. 872,483 shares traded hands during trading, a decline of 57% from the average session volume of 2,043,963 shares. The stock had previously closed at $14.81. Analyst Ratings […]

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 19,060 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $14.45, for a total value of $275,417.00. Following the transaction, the chief operating officer owned 451,540 shares in the company, valued at […]